Investigating how a specific immune receptor affects cell therapy for sepsis

Role of Toll-like Receptor 9 in Fibroblastic Reticular Cell-based Therapy for Intra-abdominal Sepsis

NIH-funded research Feinstein Institute for Medical Research · NIH-10756436

This study is looking at how a specific part of the immune system, called TLR9, works in certain cells that help fight infections, with the goal of finding better ways to treat people with serious infections in the abdomen, like sepsis.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionFeinstein Institute for Medical Research NIH-funded
Lab location1 site (Manhasset, United States)
Project IDNIH-10756436 on NIH RePORTER

What this research studies

This research focuses on understanding the role of Toll-like Receptor 9 (TLR9) in fibroblastic reticular cells (FRCs) and their potential use in treating intra-abdominal sepsis. The study explores how manipulating TLR9 signaling can enhance the effectiveness of FRC-based therapies, which have shown promise in experimental models. By examining different subsets of FRCs and their responses to sepsis, the research aims to identify mechanisms that could improve patient outcomes. Patients may benefit from insights gained into new therapeutic strategies that harness the immune system to combat sepsis.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients diagnosed with intra-abdominal sepsis or those at high risk for developing sepsis due to immune dysfunction.

Not a fit: Patients with sepsis caused by non-infectious factors or those who do not have an immune response component may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to innovative therapies that significantly reduce mortality and improve recovery rates for patients suffering from sepsis.

How similar studies have performed: Previous studies have shown success with stromal cell-based therapies in treating immune dysregulation diseases, suggesting a promising avenue for this approach in sepsis.

Where this research is happening

Manhasset, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Immune DiseasesImmune DisordersImmune System DisorderImmune System and Related DisordersImmunodeficiency and Immunosuppression Disorders
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.